Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
MS Holleman, MJ Al, R Zaim, HJM Groen… - The European Journal of …, 2020 - Springer
Objectives To compare the cost-effectiveness of first-line gefitinib, erlotinib, afatinib, and
osimertinib in patients with non-small cell lung cancer (NSCLC) harbouring epidermal …
osimertinib in patients with non-small cell lung cancer (NSCLC) harbouring epidermal …
Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore
Objective Non-small cell lung cancer (NSCLC) accounts for 80–90% of all lung cancer
cases and is usually associated with a poor prognosis. However, targeted therapy with first …
cases and is usually associated with a poor prognosis. However, targeted therapy with first …
Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung …
T Khoo, L Gao - Expert review of pharmacoeconomics & outcomes …, 2021 - Taylor & Francis
Objectives: To assess the cost-effectiveness of osimertinib versus standard epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib or erlotinib, as first …
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib or erlotinib, as first …
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
L Westerink, JLJ Nicolai, C Samuelsen… - The European Journal of …, 2020 - Springer
Background The therapeutic landscape for non-small-cell lung cancer (NSCLC) patients that
have common epidermal growth factor receptor (EGFR) mutations has changed radically in …
have common epidermal growth factor receptor (EGFR) mutations has changed radically in …
Cost‐effectiveness of osimertinib in treating newly diagnosed, advanced EGFR‐mutation‐positive non‐small cell lung cancer
Background The objective of this study was to assess cost and effectiveness of osimertinib in
treating newly diagnosed advanced non‐small cell lung cancer with an epidermal growth …
treating newly diagnosed advanced non‐small cell lung cancer with an epidermal growth …
Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
X Gu, Q Zhang, YB Chu, YY Zhao, YJ Zhang, D Kuo… - Lung Cancer, 2019 - Elsevier
Purpose Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) are
becoming the standard treatments for Chinese patients with advanced non-small cell lung …
becoming the standard treatments for Chinese patients with advanced non-small cell lung …
Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non–small cell lung cancer
Importance The survival of patients with advanced non–small cell lung cancer (NSCLC) with
epidermal growth factor receptor (EGFR) gene mutations has improved substantially in the …
epidermal growth factor receptor (EGFR) gene mutations has improved substantially in the …
Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer
E Bertranou, C Bodnar, V Dansk… - Journal of Medical …, 2018 - Taylor & Francis
Aim: This study presents the cost-utility analysis that was developed to inform the NICE
health technology assessment of osimertinib vs platinum-based doublet chemotherapy …
health technology assessment of osimertinib vs platinum-based doublet chemotherapy …
[HTML][HTML] Economic analysis of first-line treatment with erlotinib in an EGFR-mutated population with advanced NSCLC
A Vergnenegre, B Massuti, F de Marinis… - Journal of Thoracic …, 2016 - Elsevier
Introduction The cost-effectiveness of first-line tyrosine kinase inhibitor therapy in epidermal
growth factor receptor gene (EGFR)-mutated advanced-stage non–small cell lung cancer …
growth factor receptor gene (EGFR)-mutated advanced-stage non–small cell lung cancer …
[HTML][HTML] Cost-effectiveness of osimertinib for EGFR mutation–positive non–small cell lung cancer after progression following first-line EGFR TKI therapy
B Wu, X Gu, Q Zhang - Journal of Thoracic Oncology, 2018 - Elsevier
Objective The aim of this study was to investigate the cost-effectiveness of osimertinib for the
treatment of advanced NSCLC with an EGFR T790M mutation after the failure of first-line …
treatment of advanced NSCLC with an EGFR T790M mutation after the failure of first-line …